Why don't we initiate more large simple randomized controlled trials?
- Gastroduodenal Mucosa and Dyspeptic Symptoms in Arthritic Patients during Chronic Nonsteroidal Anti-Inflammatory Drug Use. Larkai, Edwin N.; Smith, J. Lacey; Lidsky, Martin D.; Graham, David Y. // American Journal of Gastroenterology;Nov1987, Vol. 82 Issue 11, p1153
Gastroduodenal intolerance is one of the major factors limiting the use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAID) in patients with arthritic conditions. We evaluated the endoscopic appearance of the gastroduodenal mucosa in 65 patients (63 men and two women) taking...
- Three nonsteroid anti-inflammatory agents for arthritis. Rodman, Morton J. // RN;Sep76, Vol. 39 Issue 9, p16
Presents information on three nonsteroid anti-inflammatory agents for arthritis. Characteristics of the drugs; Beneficial effects of the drugs; Response of patients to the drugs.
- Reactive arthritis. Svenungsson, B. // BMJ: British Medical Journal (International Edition);3/12/94, Vol. 308 Issue 6930, p671
Features reactive arthritis and the establishment of the best treatment in Great Britain. Pathophysiology of the disease; Relationship between host and the microbial factors; Treatment of reactive arthritis by the use of non-steroidal anti-inflammatory drugs.
- Safety and Efficacy of Disease-Modifying Anti-Rheumatic Agents: Focus on the Benefits and Risks of Etanercept. Fleischmann, R.; Iqbal, I.; Nandeshwar, P.; Quiceno, A. // Drug Safety;Feb2002, Vol. 25 Issue 3, p173
The traditional approach to the treatment of rheumatoid arthritis (RA) has been the use of nonsteroidal anti-inflammatory drugs usually in combination with a disease-modifying antirheumatic drug (DMARD) such as hydroxychloroquine, gold, sulfasalazine, methotrexate, leflunomide or cyclosporin....
- Healthcare Resource Utilisation and Costs of Treating NSAID-Associated Gastrointestinal Toxicity: A Multinational Perspective. Chevat, C.; Pena, B.M.; Al, M.J.; Rutten, F.F. // PharmacoEconomics;Aug2001 Supplement 1, Vol. 19 Issue 8, p17
Objective: The aim of the study was to perform an economic analysis of a new therapy in 11 countries (Australia, Belgium, Finland, France, Germany, Italy, The Netherlands, Spain, Sweden, Switzerland and the UK) to assess the cost of treating the gastrointestinal (GI) events associated with the...
- The Burden of Arthritis and Nonsteroidal Anti-Inflammatory Treatment: A European Literature Review. Hunsche, E.; Chancellor, J.V.M.; Bruce, N. // PharmacoEconomics;Aug2001 Supplement 1, Vol. 19 Issue 8, p1
The purpose of this literature review is to summarise data available from publications describing the burden of osteoarthritis and rheumatoid arthritis in Europe, and to highlight gaps in the literature. On the basis of extensive literature research, the epidemiology of arthritis, its treatment...
- The New ARTHRITIS SUPER DRUGS. Loecher, Barbara; Weiss Kiser, Sherry // Prevention;Dec2000, Vol. 52 Issue 12, p130
Focuses on the benefits and side effects of COX-2 inhibitors, a group of nonsteroidal anti-inflammatory drugs used for treating arthritis pain. INSET: Save Money, Use Fewer Drugs.
- Standard creams cut prescribing costs. // GP: General Practitioner;5/13/2002, p77
Reports on the cost-effective use of Algesal cream and Intralgin gel for arthritis. Comparison with the use of Non-Steroid Anti-Inflammatory Drug (NSAID) in treating arthritis; Cost associated with the use of NSAID; Number of patients using Algesal and Intralgin.
- What to watch for with the new arthritis drugs. White, Sara J.; Williamson, Karin // RN;Feb80, Vol. 43 Issue 2, p31
Provides information on non-steroidal anti-inflammatory agents (NSAID) used to treat arthritic patients. Mechanism of action; Negative effects of the drugs; Laboratory tests that are altered by NSAID.
- Methods for application of topical nonsteroidal anti-inflammatory drugs (TNSAIDS) in clinical trials. Gerecz-Simon, E.; kean, W. F. // Inflammopharmacology;1999, Vol. 7 Issue 3, p329
Examines the methods for application of topical non-steroidal anti-inflammatory drugs (TNSAID) in clinical trials of patients with musculoskeletal diseases. Person responsible for the application of TNSAID; Establishment of standard dosage for TNSAID; What to avoid after the application of TNSAID.